Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib) LOUISVILLE, Ky., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member of the Roche Group,...

Onco360® Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra® (tislelizumab-jsgr) LOUISVILLE, Ky., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Beigene for Tevimbra® (tislelizumab),...

OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation LOUISVILLE, Ky., April 29, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™...

Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan) LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for...

Onco360® Celebrates Excellent Patient Care, Reflected by Impressive Net Promoter Score LOUISVILLE, Ky., March 14, 2024 (GLOBE NEWSWIRE) -- This year, Onco360®, the nation’s leading independent specialty oncology pharmacy, celebrates excellent service and care that resulted in...